Redx Pharma Plc, which specialises in developing analogues of existing pharmaceuticals, has raised £15 million in an initial public offering on the AIM market in London in order to strengthen its pipeline of oncology and infectious disease assets. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
